文献速递膀胱癌与上尿路尿路上皮癌

膀胱内吉西他滨联合多西他赛与卡介苗治疗初治非肌层浸润性膀胱癌的比较:肿瘤学结局的系统综述与Meta分析

A Comparison Between Intravesical Gemcitabine Plus Docetaxel and Intravesical Bacillus Calmette-Guérin in the Treatment of Nonmuscle Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of Oncological Outcomes.
PubMed 文献 · Urology · 2025-01-09

该系统综述与Meta分析纳入3项原始研究,比较膀胱内吉西他滨联合多西他赛与标准卡介苗(BCG)治疗初治非肌层浸润性膀胱癌(NMIBC)的疗效与安全性。复发率合并比值比(OR)为0.72(95%CI:0.36-1.47),吉西他滨联合多西他赛组临床复发率略低但差异无统计学意义(Z=0.89,P=0.37);联合组严重副作用少于BCG组。因研究数量有限,需进一步随机试验确认其作用。

要点

  • 吉西他滨联合多西他赛与BCG的复发率合并OR为0.72(95%CI:0.36-1.47),差异无统计学意义。
  • 联合组临床复发率略低于BCG组,但Z=0.89、P=0.37,未达统计学显著。
  • 联合组严重副作用少于BCG组;因研究有限,需进一步随机试验确认。

核心结论

  • 膀胱内吉西他滨联合多西他赛与BCG相比,复发率无统计学显著差异,联合组严重副作用较少。
  • 因研究数量有限,需进一步随机试验确认吉西他滨联合多西他赛在NMIBC管理中的作用。

研究设计与样本

  • 系统综述与Meta分析,纳入3项原始研究,评估初治非肌层浸润性膀胱癌(NMIBC)患者的复发率与安全性。

主要发现

  • 吉西他滨联合多西他赛组与BCG组复发率之间无 heterogeneity,复发合并OR为0.72(95%CI:0.36-1.47)。
  • 吉西他滨联合多西他赛组临床复发率略低于BCG组,但差异无统计学意义(Z=0.89,P=0.37)。
  • 吉西他滨联合多西他赛组严重副作用少于BCG组。

局限性

  • 可用研究数量有限,需进一步随机试验确认膀胱内吉西他滨联合多西他赛在NMIBC管理中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study evaluated the efficacy, recurrence rates, and safety of intravesical gemcitabine plus docetaxel compared to standard Bacillus Calmette-Guérin (BCG) therapy for treating naïve non-muscle-invasive bladder cancer (NMIBC), with a focus on reducing recurrence and progression concerns associated with transurethral resection (TURBT). A systematic review and meta-analysis of three original studies were conducted, assessing recurrence rates and safety profiles. The meta-analysis revealed no heterogeneity in recurrence rates between the gemcitabine plus docetaxel and BCG groups, with an overall Odds Ratio for recurrence of 0.72 (95% CI: 0.36-1.47). Although the clinical recurrence rate was slightly lower in the gemcitabine plus docetaxel group, the difference was not statistically significant (Z = 0.89, P = 0.37). The gemcitabine plus docetaxel group experienced fewer severe side effects compared to the BCG group. Due to the limited number of studies available, further randomized trials are necessary to confirm the role of intravesical gemcitabine plus docetaxel in NMIBC management.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Tripathy R, Kumar L, Agarwal S, et al. A Comparison Between Intravesical Gemcitabine Plus Docetaxel and Intravesical Bacillus Calmette-Guérin in the Treatment of Nonmuscle Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of Oncological Outcomes. Urology. 2025. PMID: 39798618. doi:10.1016/j.urology.2025.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。